Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01184846

Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trial

Official title:
A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Clinical Trial Summary

The objective of this study is to demonstrate the efficacy and safety of Privigen in subjects with CIDP.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Polyneuropathies
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Clinical Trial Details
NCT number NCT01184846
Study type Interventional
Source CSL Behring
Contact
Status Completed
Phase Phase 3
Start date November 2010
Completion date November 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT02465359 - Subcutaneous Immunoglobulin for CIDP N/A
Recruiting NCT05584631 - IVIG vs SCIG in CIDP Phase 1
Withdrawn NCT01236456 - High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Phase 2
Terminated NCT03779828 - Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
Recruiting NCT05011006 - NT-3 Levels and Function in Individuals With CMT
Recruiting NCT06290141 - A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 3
Completed NCT01379833 - Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Completed NCT02414490 - IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
Completed NCT01545076 - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Phase 3
Active, not recruiting NCT00716066 - Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases Phase 2
Recruiting NCT04672733 - Hizentra® in Inflammatory Neuropathies - pHeNIx Study
Not yet recruiting NCT04480450 - Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy Phase 2
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Not yet recruiting NCT05219383 - Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy
Completed NCT02111590 - Immunoglobulin Dosage and Administration Form in CIDP and MMN N/A
Recruiting NCT04292834 - A Registered Cohort Study of Immune-Mediated Neuropathies
Terminated NCT03772717 - Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) N/A
Completed NCT00278629 - Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Phase 2
Recruiting NCT02372149 - IVIg for Demyelination in Diabetes Mellitus Phase 4
Completed NCT00962429 - Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Phase 2